The expanded CAG repeat that causes HD sits within the very beginning of the huntingtin gene. Sometimes the huntingtin ...

A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, ...

Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering ...

We’re pleased to announce the 2026 HDBuzz Prize! This year, the HDBuzz Prize is brought to you by the Hereditary Disease ...

The outcomes of the GENERATION HD1 trial have just been published in a scientific journal, nearly three years after the study was halted. In March of 2021, the HD community was hit with the difficult ...

SOM3355 is an investigational therapy aimed at managing multiple symptoms of Huntington’s disease (HD) and recently crossed two key regulatory milestones. In September, the European Medicines Agency ...

In plain language. Written by scientists. For the global HD community.

We’re proud to announce Chloe Langridge as a 2025 HDBuzz Prize winner! A protein called SGTA shows promise as a target in HD therapeutics. Researchers find that increasing levels of SGTA in the cell ...

Votoplam, the daily pill from PTC Therapeutics, has met its primary endpoint in the PIVOT-HD clinical trial – it can lower huntingtin protein levels. This latest data update also provides insights ...

We learned on July 25, 2025 that Prilenia’s application to the European Medicines Agency’s (EMA) for pridopidine was not accepted for marketing authorization. While this is perhaps not surprising ...

In an update from uniQure, they report that their experimental gene therapy, AMT-130, has the potential to slow Huntington’s disease progression in key clinical study. HD is caused by a faulty copy of ...

Today, Roche announced in a community letter difficult news for the Huntington’s disease (HD) community, discontinuing two separate clinical programmes after new data emerged from ongoing studies. The ...